Loading organizations...
§ Public · Waltham, MA, USA
Viridian Therapeutics is a technology company.
Viridian Therapeutics develops optimized treatments for rare autoimmune conditions, leveraging expertise in antibody discovery and engineering. The company designs potential best-in-class medicines by targeting validated pathways. Key programs address Thyroid Eye Disease (TED) and include FcRn portfolio strategies, aiming to fulfill significant unmet patient needs.
The company originated as miRagen Therapeutics, incorporated in 2007 by co-founders Eric Newell Olson and William Marshall. Initially focused on microRNA therapeutics, the organization evolved. After an October 2020 acquisition and January 2021 rebrand, it became Viridian Therapeutics, focusing on antibody discovery for rare autoimmune diseases.
Viridian Therapeutics primarily serves patients with serious rare autoimmune conditions, particularly Thyroid Eye Disease, where existing treatment options are often insufficient. The company’s vision is to improve patient care by providing optimized, effective therapeutics. It aims to reshape the treatment landscape, enhancing patient outcomes and quality of life.
Viridian Therapeutics has raised $89.0M across 6 funding rounds.
Viridian Therapeutics has raised $89.0M in total across 6 funding rounds.
Viridian Therapeutics has raised $89.0M in total across 6 funding rounds.
Viridian Therapeutics's investors include Jafco Ventures, Joshua Resnick, Atlas Venture, MPM Capital, Amgen Ventures, Boulder Ventures, Brace Pharma Capital, MP Healthcare Venture Management, Remeditex Ventures, Broadview Ventures, John Creecy.
I need to clarify an important point: Viridian Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing medicines for autoimmune and rare diseases.
Based on the search results provided, here's what we know about Viridian:
Viridian Therapeutics is a biopharmaceutical company leveraging antibody discovery and engineering expertise to develop optimized treatments for rare autoimmune conditions[1][2]. The company was founded with a mission to significantly improve treatment options for autoimmune and rare diseases, with a particular focus on thyroid eye disease (TED)[1]. Viridian aims to provide patients with therapies that are safe, effective, and easy to use, enabling them to live full, healthy lives[1].
The search results provided contain limited details about Viridian's founding history, specific product pipeline, financial performance, or market position. To provide a comprehensive analysis matching your requested framework (origin story, role in broader landscape, and future outlook), additional sources would be needed covering the company's founding timeline, key leadership backgrounds, clinical trial data, and competitive positioning within the biopharmaceutical sector.
If you're researching Viridian as a potential investment or partnership opportunity, I'd recommend seeking more detailed information about their clinical pipeline, regulatory status, and market opportunity in rare autoimmune diseases.
Viridian Therapeutics has raised $89.0M across 6 funding rounds. Most recently, it raised $41.0M Series C in November 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2015 | $41M Series C | Jafco Ventures, Joshua Resnick | Atlas Venture, MPM Capital, Amgen Ventures, Boulder Ventures, Brace Pharma Capital, MP Healthcare Venture Management, Remeditex Ventures | Announced |
| Feb 1, 2015 | $9M Series B | — | Atlas Venture, Broadview Ventures, MPM Capital | Announced |
| Jun 1, 2014 | $7M Series B | — | Atlas Venture, Broadview Ventures, MPM Capital | Announced |
| Apr 1, 2012 | $20M Series B | John Creecy | Atlas Venture, Broadview Ventures, MPM Capital, Amgen Ventures, Boulder Ventures, Broadview Ventures | Announced |
| Jun 1, 2009 | $4M Series A | — | Atlas Venture, MPM Capital | Announced |
| May 1, 2008 | $8M Series A | — | Atlas Venture, MPM Capital | Announced |